Cargando…

Immature Oocyte for Fertility Preservation

In vitro maturation (IVM) of human immature oocytes has been offered to women who are at risk of developing ovarian hyperstimulation syndrome (OHSS) caused by gonadotropin stimulation, such as PCO(S) patients or who have poor ovarian reserve. Cryopreservation of oocytes matured in vivo obtained in I...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Weon-Young, Henderson, Sara, Cohen, Yoni, Dahan, Michael, Buckett, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650526/
https://www.ncbi.nlm.nih.gov/pubmed/31379739
http://dx.doi.org/10.3389/fendo.2019.00464
_version_ 1783438147122626560
author Son, Weon-Young
Henderson, Sara
Cohen, Yoni
Dahan, Michael
Buckett, William
author_facet Son, Weon-Young
Henderson, Sara
Cohen, Yoni
Dahan, Michael
Buckett, William
author_sort Son, Weon-Young
collection PubMed
description In vitro maturation (IVM) of human immature oocytes has been offered to women who are at risk of developing ovarian hyperstimulation syndrome (OHSS) caused by gonadotropin stimulation, such as PCO(S) patients or who have poor ovarian reserve. Cryopreservation of oocytes matured in vivo obtained in IVF cycles has improved after implementing the vitrification method and many successful results have been reported. Now, this procedure can be successfully offered to fertility preservation programs for patients who are in danger of losing their ovarian function due to medical or social reasons, and to oocyte donation programs. This vitrification technique has also been applied to cryopreserve oocytes obtained from IVM program. Some advantages of oocytes vitrification related with IVM are: (1) eliminating costly drugs and frequent monitoring; (2) completing treatment within 2 to 10 days (3) avoiding the use of hormones in cancer patients with hormone-sensitive tumors; and (4) retrieving oocytes at any point in menstrual cycle, even in the luteal phase. In addition, immature oocytes can also be collected from extracorporeal ovarian biopsy specimens or ovaries during caesarian section. Theoretically, there are two possible approaches for preserving immature oocytes: oocyte cryopreservation at the mature stage (after IVM) and oocyte cryopreservation at the Germinal Vesicle (GV)-stage (before IVM). Both vitrification of immature oocyte before/after IVM is not currently satisfactory. Nevertheless, many IVF centers worldwide are doing IVM oocyte cryopreservation as one of the options to preserve fertility for female cancer. Therefore, more studies are urgently required to improve IVM- and vitrification method to successfully preserve oocytes collected from cancer patients. In this review, present oocyte maturation mechanisms and recent progress of human IVM cycles will be discussed first, followed by some studies of the vitrification of human IVM oocyte.
format Online
Article
Text
id pubmed-6650526
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66505262019-08-02 Immature Oocyte for Fertility Preservation Son, Weon-Young Henderson, Sara Cohen, Yoni Dahan, Michael Buckett, William Front Endocrinol (Lausanne) Endocrinology In vitro maturation (IVM) of human immature oocytes has been offered to women who are at risk of developing ovarian hyperstimulation syndrome (OHSS) caused by gonadotropin stimulation, such as PCO(S) patients or who have poor ovarian reserve. Cryopreservation of oocytes matured in vivo obtained in IVF cycles has improved after implementing the vitrification method and many successful results have been reported. Now, this procedure can be successfully offered to fertility preservation programs for patients who are in danger of losing their ovarian function due to medical or social reasons, and to oocyte donation programs. This vitrification technique has also been applied to cryopreserve oocytes obtained from IVM program. Some advantages of oocytes vitrification related with IVM are: (1) eliminating costly drugs and frequent monitoring; (2) completing treatment within 2 to 10 days (3) avoiding the use of hormones in cancer patients with hormone-sensitive tumors; and (4) retrieving oocytes at any point in menstrual cycle, even in the luteal phase. In addition, immature oocytes can also be collected from extracorporeal ovarian biopsy specimens or ovaries during caesarian section. Theoretically, there are two possible approaches for preserving immature oocytes: oocyte cryopreservation at the mature stage (after IVM) and oocyte cryopreservation at the Germinal Vesicle (GV)-stage (before IVM). Both vitrification of immature oocyte before/after IVM is not currently satisfactory. Nevertheless, many IVF centers worldwide are doing IVM oocyte cryopreservation as one of the options to preserve fertility for female cancer. Therefore, more studies are urgently required to improve IVM- and vitrification method to successfully preserve oocytes collected from cancer patients. In this review, present oocyte maturation mechanisms and recent progress of human IVM cycles will be discussed first, followed by some studies of the vitrification of human IVM oocyte. Frontiers Media S.A. 2019-07-17 /pmc/articles/PMC6650526/ /pubmed/31379739 http://dx.doi.org/10.3389/fendo.2019.00464 Text en Copyright © 2019 Son, Henderson, Cohen, Dahan and Buckett. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Son, Weon-Young
Henderson, Sara
Cohen, Yoni
Dahan, Michael
Buckett, William
Immature Oocyte for Fertility Preservation
title Immature Oocyte for Fertility Preservation
title_full Immature Oocyte for Fertility Preservation
title_fullStr Immature Oocyte for Fertility Preservation
title_full_unstemmed Immature Oocyte for Fertility Preservation
title_short Immature Oocyte for Fertility Preservation
title_sort immature oocyte for fertility preservation
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650526/
https://www.ncbi.nlm.nih.gov/pubmed/31379739
http://dx.doi.org/10.3389/fendo.2019.00464
work_keys_str_mv AT sonweonyoung immatureoocyteforfertilitypreservation
AT hendersonsara immatureoocyteforfertilitypreservation
AT cohenyoni immatureoocyteforfertilitypreservation
AT dahanmichael immatureoocyteforfertilitypreservation
AT buckettwilliam immatureoocyteforfertilitypreservation